Pfizer in diabetes drug deal with Sciwind Biosciences

SHANGHAI, Feb 24 (Reuters) - Pfizer has entered an agreement to license Sciwind Biosciences' type 2 diabetes treatment ...

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Agreement worth up to $495 million is part of a growing number of Chinese deals with global pharma giants as the country ...

Pfizer nabs China obesity drug rights in $495 million deal

Pfizer Inc. has acquired exclusive rights to commercialize an obesity therapy in China, strengthening its push into the fast-growing weight loss market.
Fierce Pharma

Pfizer snaps up rights to commercialize diabetes GLP-1 in China

More recently, Pfizer splashed out $150 million upfront—and put up hundreds of millions more in potential milestones—to acquire worldwide rights to a GLP-1 agonist dubbed YP05002 from Yao Pharma, a ...
KTVU

Pfizer: COVID-19 pill remains effective against severe disease, omicron variant

WASHINGTON - Pfizer said Tuesday that its experimental COVID-19 pill appears effective against the omicron variant. The company also said full results of its 2,250-person study confirmed the pill's ...
abc7NY

Pfizer's COVID-19 pill reduces risk of being hospitalized or dying by 89%, company says

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...
ABC 7 Chicago

Phase 2, 3 trial for Pfizer pill for COVID begins in children ages 6 to 17

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will ...